

## B-Engrossed Senate Bill 698

Ordered by the House May 23  
Including Senate Amendments dated April 15 and House Amendments  
dated May 23

Sponsored by Senator MONNES ANDERSON, Representatives NOSSE, GREENLICK; Senators BEYER, BURDICK, DEMBROW, FAGAN, KNOPP, MANNING JR, STEINER HAYWARD, THATCHER, Representatives ALONSO LEON, GORSEK, HAYDEN, KENY-GUYER, MCLAIN, MEEK, MITCHELL, PILUSO, POWER, PRUSAK, REARDON, SALINAS, SANCHEZ, SCHOUTEN, WILDE

### SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure.

Directs State Board of Pharmacy to adopt rules to require **that** prescription drugs [*for specified persons*] be labeled [*or dispensed with informational insert*] in English and other language **upon request of practitioner, patient or patient representative**. [*Specifies languages other than English to be used on label and insert and allows board to require additional languages.*] **Allows board to determine prescription drugs for which additional informational insert in English and other language may be included. Requires that labels and informational inserts be available in at least 14 languages other than English. Directs board to update available languages at least once every 10 years. Exempts institutional drug outlets from requirements.**

Directs board to adopt rules to require pharmacy to post signage regarding patients' right to free, competent oral interpretation and translation services.

Becomes operative January 1, 2021.

Takes effect on 91st day following adjournment sine die.

### A BILL FOR AN ACT

1  
2 Relating to prescription drug labeling; creating new provisions; amending ORS 689.505; and pre-  
3 scribing an effective date.

4 **Be It Enacted by the People of the State of Oregon:**

5 **SECTION 1. Section 2 of this 2019 Act is added to and made a part of ORS chapter 689.**

6 **SECTION 2. (1) The State Board of Pharmacy shall adopt rules to require that, if a pa-**  
7 **tient is of limited English proficiency and the prescribing practitioner, patient or an au-**  
8 **thorized representative of the patient so requests, a prescription drug dispensed by a**  
9 **pharmacy bear a label in both English and in the language requested and, if authorized by**  
10 **the board by rule, include an informational insert in both English and the language re-**  
11 **quested. The rules adopted under this section must:**

12 (a) Define "limited English proficiency."

13 (b) Determine the pharmacies to which the requirements of this section apply, and in-  
14 clude at least retail drug outlets and other drug outlets that dispense prescription drugs.

15 (c) Determine for which prescription drugs it is appropriate to include an informational  
16 insert in addition to the label. In adopting rules under this paragraph, the board shall con-  
17 sider the complexity and length of the directions for use of the prescription drug.

18 (d)(A) Require that labels and informational inserts be available in at least 14 languages  
19 other than English that are spoken in Oregon by individuals who are of limited English pro-  
20 ficiency, as determined by the most recent American Community Survey from the United

**NOTE:** Matter in **boldfaced** type in an amended section is new; matter [*italic and bracketed*] is existing law to be omitted.  
New sections are in **boldfaced** type.

1 States Census Bureau and in consultation with the Oregon Health Authority and other nec-  
2 essary resources.

3 (B) Require the board to reassess, and update as necessary, the languages described in  
4 this paragraph at least once every 10 years, in consultation with the authority and other  
5 stakeholders.

6 (2)(a) A pharmacy may contract with a third party for the translation of the labels and  
7 informational inserts required under subsection (1) of this section.

8 (b) A pharmacy, pharmacist or pharmacy intern that dispenses a prescription drug in  
9 compliance with the requirements of subsection (1) of this section may not be held liable for  
10 injuries resulting from the actions of a third party if the pharmacy from which the label or  
11 informational insert was dispensed entered into a contract with the third party in good faith,  
12 and the pharmacy, pharmacist or pharmacy intern was not negligent with regard to the al-  
13 leged misconduct of the third party.

14 (3) This section does not apply to an institutional drug outlet.

15 (4) The board may adopt other rules as necessary to carry out this section.

16 (5) The board shall, in consultation with the Oregon Health Authority, adopt rules to  
17 require that a pharmacy post signage to provide notification of the right to free, competent  
18 oral interpretation and translation services for patients who are of limited English profi-  
19 ciency. Rules adopted under this subsection must comply with any relevant federal laws and  
20 regulations.

21 **SECTION 3.** ORS 689.505 is amended to read:

22 689.505. (1)(a) Except as specifically provided by law **and in compliance with section 2 of this**  
23 **2019 Act**, [no person shall] **a person may not** distribute or dispense any drug without affixing to  
24 the authorized container a clear and legible label, either printed or written, bearing the name of the  
25 drug and the name and place of business of the person distributing or dispensing the drug, and any  
26 other information required by state law or rules or federal law or regulations under whose super-  
27 vision the drug is delivered or dispensed.

28 (b) Labeling requirements regarding any drug may be changed or exemption therefrom granted  
29 by the State Board of Pharmacy in the form of a special permit if the board determines that a  
30 change or exemption is in the best interest of public health and safety.

31 (2)(a) [No] **A** manufacturer or wholesaler subject to ORS 689.305 [shall] **may not** sell or other-  
32 wise distribute, or offer to sell or otherwise distribute, any drug for use in a:

33 (A) Parcel, package or container not bearing a label specifying the name, active ingredients or  
34 contents, quality and quantity of the drug.

35 (B) Misbranded parcel, package or container.

36 (b) A parcel, package or container is misbranded:

37 (A) If its labeling is false or misleading in any particular.

38 (B) Unless it bears a label containing the name and business address of the manufacturer,  
39 packer, distributor or wholesaler, and an accurate statement of the quantity of the drug in terms  
40 of weight, measure or numerical count, exclusive of wrappers, cartons, containers or other materials  
41 packed with such drug.

42 (C) In case it contains controlled substances [which] **that** the board finds and by rule designates  
43 after reasonable notice and opportunity for hearing to be habit forming, unless it bears the state-  
44 ment "Warning--May Be Habit Forming."

45 (D) Unless it bears a label with adequate directions for the safe use of the drug for specified

1 conditions, and adequate warning against use in those pathological conditions or by children where  
2 such use may be dangerous to the health or welfare of a user.

3 (E) Unless it bears a label with true representations of the intended uses of the drug and no  
4 false claims or representations are made of the drug in accompanying literature or advertising.

5 (3) This section does not apply to parcels, packages or containers containing:

6 (a) Drugs prepared and packaged solely for use by a pharmacist in compounding prescriptions  
7 or for dispensing in dosage unit form upon a prescription, except that such parcels, packages or  
8 containers must bear the name and business address of the manufacturer and, if different, the name  
9 and business address of the distributor of the drug, and the legend "Caution: Federal Law Prohibits  
10 Dispensing Without Prescription" or an equivalent legend.

11 (b) Drugs intended solely for use in the professional diagnosis of disease, except that such par-  
12 cels, packages or containers shall bear the statement "Diagnostic Reagent--For Professional Use  
13 Only."

14 (c) Coloring agents, emulsifiers, excipients, flavorings, lubricants, preservatives and other like  
15 inactive ingredients used in the manufacture of drugs.

16 (4) The board shall by rule exempt from any labeling or packaging requirement of this section  
17 drugs [*which*] **that** are, in accordance with the practice of the trade, to be processed, labeled or  
18 repacked in substantial quantities at establishments other than those where originally processed or  
19 packed. However, such drugs must not be adulterated or misbranded upon removal from such pro-  
20 cessing, labeling or repacking establishment.

21 (5) A pharmacist or pharmacy intern [*shall*] **may** not dispense, on the prescription of a practi-  
22 tioner, any drug without affixing to the container thereof a clear and legible label. The label may  
23 be printed or written. Except as provided in subsection (6) of this section, the pharmacist or phar-  
24 macy intern shall state or cause to be stated on the label the following:

25 (a) The name of the drug. If the dispensed drug does not have a brand name, the prescription  
26 label shall indicate the generic name of the drug dispensed along with the name of the drug dis-  
27 tributor or manufacturer, its quantity per unit and the directions for its use stated in the pre-  
28 scription. However, if the drug is a compound, the quantity per unit need not be stated.

29 (b) The name of the practitioner prescribing the drug.

30 (c) The name and place of business of the pharmacist or the name and place of business of the  
31 pharmacy for which the pharmacist or pharmacy intern is acting.

32 (d) The name of the patient, unless the drug is prescribed to a partner of a patient as defined  
33 in ORS 676.350 in accordance with rules adopted under ORS 676.350 authorizing the practice of ex-  
34 pedited partner therapy.

35 (e) When applicable and as determined by the [*State Board of Pharmacy*] **board**, an expiration  
36 date after which the patient should not use the drug.

37 (6) If the prescribing practitioner so directs, the prescription label [*shall*] **may** not state the  
38 name and quantity per unit of the drug.

39 (7) The [*State Board of Pharmacy*] **board** shall determine those drugs [*which*] **that** must bear  
40 an expiration date under subsection (5)(e) of this section.

41 (8) As used in this section, "compound" means a drug containing two or more medically active  
42 ingredients.

43 (9) [*No*] **A** person [*shall*] **may not** deliver or dispense any drug for use by the ultimate consumer  
44 without labeling the drug container as required in this section.

45 (10) In addition to the labeling requirements imposed by subsections (1) to (9) of this section, the

1 board may impose by rule requirements for drug code imprints on solid dose legend drugs.

2 **SECTION 4. (1) Section 2 of this 2019 Act and the amendments to ORS 689.505 by section**  
3 **3 of this 2019 Act become operative on January 1, 2021.**

4 **(2) The State Board of Pharmacy may take any action before the operative date specified**  
5 **in subsection (1) of this section that enables the board to exercise, on or after the operative**  
6 **date specified in subsection (1) of this section, all of the duties, functions and powers con-**  
7 **ferred on the board by section 2 of this 2019 Act and the amendments to ORS 689.505 by**  
8 **section 3 of this 2019 Act.**

9 **SECTION 5. This 2019 Act takes effect on the 91st day after the date on which the 2019**  
10 **regular session of the Eightieth Legislative Assembly adjourns sine die.**

11